News for IDEAYA Biosciences, Inc. (IDYA)

Stocks Analysis by Investing.com (Chinmay Pandya) covering: Ionis Pharmaceuticals Inc, Lattice Semiconductor Corporation, Manchester United Ltd, Five Below Inc. Read Investing.com (Chinmay Pandya)'s latest article on Investing.com

On December 31, 2024, JANUS HENDERSON GROUP PLC (Trades, Portfolio) made a significant move by acquiring an additional 695,263 shares of IDEAYA Biosciences Inc

The heavy selling pressure might have exhausted for IDEAYA Biosciences (IDYA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

IDEAYA Biosciences (IDYA) delivered earnings and revenue surprises of -122.39% and 0%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

IDEAYA Biosciences Inc (IDYA), a precision medicine oncology company, has released its financial results for the fourth quarter and full year ending December 31

Summary IDEAYA Biosciences Inc (IDYA), a precision medicine oncology company, announced on February 13, 2025, a new clinical study collaboration and supply agre

PR NewswireSOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and me

PR NewswireSOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 Entered into an additional clinical study collaboration and supply agreement with Gilead to evaluate

IDEAYA Biosciences, Inc. (IDYA), Thursday announced an additional clinical study collaboration and supply agreement with Gilead Sciences, Inc. (GILD) to evaluate the efficacy and safety of IDE397, in combination with the latter's Trodelvy in methylthioadenosine phosphorylase or MTAP-deletion non-small cell lung cancer or NSCLC.

Ideaya is financially strong, with $1.2 billion in cash reserves, sufficient to fund operations into at least 2028. Click here to read why IDYA is a Strong Buy.

IDEAYA Biosciences (IDYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Summary IDEAYA Biosciences Inc (IDYA), a precision medicine oncology company, announced on February 10, 2025, the appointment of Joshua Bleharski, Ph.D., as Chi

A lot is happening in the market, especially within the growth sectors.

IDEAYA Biosciences Inc (IDYA), a leader in precision medicine oncology, announced on January 27, 2025, its participation in two significant investor relations e

PR NewswireSOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a

Ideaya stock touches 52-week low at $22.15 amid market challenges

Summary IDEAYA Biosciences Inc (IDYA), a leader in precision medicine oncology, announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference

PR NewswireSOUTH SAN FRANCISCO, Calif., Jan. 12, 2025 SOUTH SAN FRANCISCO, Calif., Jan. 12, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a

IDEAYA Biosciences Inc (IDYA), a precision medicine oncology company, announced on December 29, 2024, that it has entered into an exclusive global license agree